Pfizer’s Comirnaty Vaccine Sales Drop Significantly
Sales of Pfizer’s Comirnaty vaccine in the U.S. have seen a sharp decline following the recent update of the vaccination schedule by the Trump administration. This change included the withdrawal of universal recommendations for the coronavirus vaccine.
In the third quarter of 2025, Pfizer reported a revenue drop of 6% compared to the same time last year, translating to a loss of about $1 billion.
According to Pfizer’s latest financial report, “The decline in operations was mainly due to reduced revenue from COVID-19 products, which was influenced by lower infection rates. This also affected demand for Paxlovid, and there was a smaller target population for Comirnaty due to a decrease in vaccine recommendations in the U.S.”
Sales of Comirnaty dropped by 25% in the U.S., while Paxlovid sales, an antiviral medication for mild to moderate coronavirus infections, fell by a staggering 52%.
Recently, the CDC withdrew its universal recommendation for Comirnaty. This decision follows a period when national immunity was improving but amid debates surrounding the efficacy of the vaccine. Approximately 1% of confirmed cases have been noted, according to Jim O’Neill, the Acting Director of the CDC.
O’Neill pointed out that the CDC’s previous blanket recommendation for a permanent COVID-19 booster in 2022 might have stifled conversations regarding the risks and benefits of vaccination for individual patients. He indicated a shift towards a more personalized approach moving forward.
The CDC’s recent decision comes soon after the FDA required Pfizer to issue a stern warning regarding the Comirnaty vaccine, citing potential heart disease risks linked to the vaccine for the 2023-2024 cycle. A study also highlighted instances of myocarditis related to vaccinations among American youth.
The FDA noted that for those aged 6 months to 64 years, the incidence of myocarditis or pericarditis within a week after receiving the 2023-2024 Combination COVID-19 mRNA Vaccine was about 8 cases per million doses. For males aged 12 to 24, this figure was approximately 27 cases per million doses.
Currently, the FDA has authorized the use of the vaccine for individuals aged 65 and older, or those between 5 and 64 with certain underlying health conditions that may lead to severe outcomes from COVID-19. Additionally, the company had to revoke the emergency use authorization for the vaccine back in August.
Pfizer’s CEO, Albert Bourla, mentioned in a call with analysts that the company’s vaccine portfolio is seen as a crucial area of interest internationally, hinting at possible opportunities beyond U.S. borders.
